炎症生物标志物C反应蛋白与多民族乳腺癌人群放疗诱导早期皮肤不良反应的关联
该前瞻性研究纳入1000例接受放疗的乳腺癌患者,评估高敏C反应蛋白(hsCRP)与放疗诱导早期皮肤毒性的关联。多变量分析显示,肥胖、放疗后hsCRP≥4.11 mg/L及两者联合与4级及以上皮肤毒性显著相关;非肥胖患者中放疗后hsCRP高于中位数及hsCRP变化亦与4级及以上毒性显著相关。
要点
- 放疗后hsCRP≥4.11 mg/L与4级及以上皮肤毒性独立相关(OR 1.61)。
- 肥胖与hsCRP联合时4级及以上皮肤毒性风险显著增高(OR 3.65)。
- 非肥胖患者中hsCRP变化与4级及以上皮肤毒性显著相关(OR 2.80)。
核心结论
- hsCRP可作为乳腺癌放疗诱导皮肤毒性的炎症生物标志物,非肥胖患者放疗相关hsCRP升高者4级及以上皮肤毒性风险显著增加。
研究设计与样本
- 2011至2013年前瞻性评估1000例接受放疗的乳腺癌患者,通过Wake Forest University Community Clinical Oncology Program Research Base进行。
- 采用放疗前后血浆hsCRP水平及肿瘤护理学会皮肤毒性标准(0至6级)评估皮肤毒性,并应用多变量逻辑回归分析。
主要发现
- 约42%患者发生3级及以上皮肤毒性,15%发生4级及以上皮肤毒性。
- hsCRP水平因种族和体重指数而显著不同,但不因族裔而不同。
- 多变量分析中,4级及以上皮肤毒性与肥胖(OR 2.17;95%CI 1.41-3.34)、放疗后hsCRP≥4.11 mg/L(OR 1.61;95%CI 1.07-2.44)及两者联合(OR 3.65;95%CI 2.18-6.14)显著相关。
- 非肥胖患者中,放疗后hsCRP高于中位数(OR 1.93;95%CI 1.03-3.63)及hsCRP变化(OR 2.80;95%CI 1.42-5.54)与4级及以上皮肤毒性显著相关。
关键数值与推荐
- 皮肤毒性采用肿瘤护理学会标准(0至6级)评估。
- 放疗后hsCRP阈值4.11 mg/L用于分析4级及以上皮肤毒性关联。
临床怎么用
- 可考虑监测放疗前后hsCRP水平以辅助预测乳腺癌患者放疗诱导的严重皮肤毒性风险。
- 对肥胖及非肥胖患者中hsCRP升高者应加强皮肤毒性监测与临床决策。
局限性
- 研究为观察性设计,不能确立因果关系。
- hsCRP与皮肤毒性的关联可能受未测量混杂因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose This study examined an inflammatory biomarker, high-sensitivity C-reactive protein (hsCRP), in radiotherapy (RT)-induced early adverse skin reactions or toxicities in breast cancer. Patients and Methods Between 2011 and 2013, 1,000 patients with breast cancer who underwent RT were evaluated prospectively for skin toxicities through the National Cancer Institute-funded Wake Forest University Community Clinical Oncology Program Research Base. Pre- and post-RT plasma hsCRP levels and Oncology Nursing Society skin toxicity criteria (0 to 6) were used to assess RT-induced skin toxicities. Multivariable logistic regression analyses were applied to ascertain the associations between hsCRP and RT-induced skin toxicities after adjusting for potential confounders. Results The study comprised 623 white, 280 African American, 64 Asian/Pacific Islander, and 33 other race patients; 24% of the patients were Hispanic, and 47% were obese. Approximately 42% and 15% of patients developed RT-induced grade 3+ and 4+ skin toxicities, respectively. The hsCRP levels differed significantly by race and body mass index but not by ethnicity. In multivariable analysis, grade 4+ skin toxicity was significantly associated with obesity (odds ratio [OR], 2.17; 95% CI, 1.41 to 3.34], post-RT hsCRP ≥ 4.11 mg/L (OR, 1.61; 95% CI, 1.07 to 2.44), and both factors combined (OR, 3.65; 95% CI, 2.18 to 6.14). Above-median post-RT hsCRP (OR, 1.93; 95% CI, 1.03 to 3.63), and change in hsCRP (OR, 2.80; 95% CI, 1.42 to 5.54) were significantly associated with grade 4+ skin toxicity in nonobese patients. Conclusion This large prospective study is the first to our knowledge of hsCRP as an inflammatory biomarker in RT-induced skin toxicities in breast cancer. We demonstrate that nonobese patients with elevated RT-related change in hsCRP levels have a significantly increased risk of grade 4+ skin toxicity. The outcomes may help to predict RT responses and guide decision making.
引用
- Hu JJ, Urbanic JJ, Case LD, et al. Association Between Inflammatory Biomarker C-Reactive Protein and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer Population. J Clin Oncol. 2018. PMID: 29989859. doi:10.1200/JCO.2017.77.1790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。